Shortening treatment of tuberculosis: Lessons from fluoroquinolone trials

The Lancet Infectious Diseases

Volumn 15, Issue 2, 2015, Pages 141-143

  Nimmo, Camus ^a   Lipman, Marc ^a,c   Phillips, Patrick P J ^b   McHugh, Timothy ^b   Nunn, Andrew ^b   Abubakar, Ibrahim ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

BACTERIAL LOAD; CASE FINDING; DRUG DOSE INCREASE; FOLLOW UP; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR DIAGNOSTICS; NONHUMAN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SCALE UP; SPUTUM SMEAR; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULOSIS; CLINICAL TRIAL (TOPIC); DRUG THERAPY; PROCEDURES; TIME;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; FLUOROQUINOLONES; HUMANS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84921063513     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70885-0     Document Type: Note

References (14)

1. Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014, 14:327-340.
2. Priorities for tuberculosis research WHO, (accessed Nov 1, 2014). http://apps.who.int/iris/bitstream/10665/85888/1/9789241505970_eng.pdf.
3. Johnson JL, Hadad DJ, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009, 180:558-563.
4. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1989, 139:871-876.
5. Ziganshina LE, Titarenko AF, Davies GR Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database Syst Rev 2013, 6. CD004795.
6. Lounis N, Bentoucha A, Truffot-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001, 45:3482-3486.
7. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014, 371:1599-1608.
8. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014, 371:1588-1598.
9. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014, 371:1577-1587.
10. Jawahar MS, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One 2013, 8:e67030.
11. Phillips PP, Nunn AJ, Paton NI Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months?. Int J Tuberc Lung Dis 2013, 17:807-809.
12. Chang KC, Sterling TR, Yew WW Are we ready to shorten the treatment duration for non-cavitary pulmonary tuberculosis?. Int J Tuberc Lung Dis 2013, 17:712.
13. Honeyborne I, Mtafya B, Phillips PP, et al. The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment. J Clin Microbiol 2014, 52:3064-3067.
14. Phillips PP, Gillespie SH, Boeree M, et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis 2012, 205(suppl 2):S250-S257.